Understanding how the timing of exposure to endogenous hormones influences cancer development is critical to elucidating disease etiology. Prolactin increases proliferation and cell motility, processes important in later stage tumor development, suggesting that levels proximate (versus distant) to diagnosis may better predict risk. Thus, we calculated relative risks (RR) and 95% confidence intervals (CI) for prolactin levels on samples collected <10 (proximate) versus !10 (distant) years before diagnosis in the Nurses' Health Study (NHS) and NHSII with breast cancer risk, including in a subset of NHS women providing two samples 10 years apart. We measured prolactin via immunoassay in cases diagnosed from 1990 to 2010 (NHS) and 1999 to 2009 (NHSII) and matched controls. Overall, 2,468 cases and 4,021 controls had prolactin measured <10 years and 953 cases and 1,339 controls >10 years before diagnosis/reference date. There was an increased risk for higher proximate prolactin levels [RR, >15.7 vs. 8.1 ng/mL (i.e., top vs. bottom quartiles) ¼ 1.20; 95% CI, 1.03-1.40; P trend ¼ 0.005], but not for distant levels (RR ¼ 0.97; P trend ¼ 0.94); results were similar among women with two blood samples (P interaction , proximate vs. distant ¼ 0.07). The positive association was stronger for ER þ disease (RR ¼ 1.28; P trend ¼ 0.003) and postmenopausal women (RR ¼ 1.37; P trend ¼ 0.0002). Among postmenopausal women, the association was strongest for ER þ disease (RR ¼ 1.52) and lymph node-positive cases (RR ¼ 1.63). Our data suggest that prolactin levels measured <10 years before diagnosis are most strongly associated with postmenopausal breast cancer risk, especially for ER þ tumors and metastatic disease. This corresponds with biologic data that prolactin is etiologically important in tumor promotion. Cancer Res; 73(15); 4810-9. Ó2013 AACR.
Introduction
Prolactin is an important growth hormone involved in breast development and lactation (1) that has been positively associated with breast cancer risk in two large prospective studies (2, 3) , although three smaller studies did not observe a significant association (4) (5) (6) . Furthermore, a study of 384 patients with hyperprolactinemia did not observe an increased risk of breast cancer (7) . Experimental data strongly support a role of prolactin in breast cancer development, particularly by increasing cell proliferation, tumor vascularization, and cell motility, which are important in promoting late-stage carcinogenesis and, possibly, metastasis (1, 8) . This suggests that high levels of circulating prolactin may be more strongly associated with more aggressive breast cancer phenotypes or when measured more proximate to diagnosis. However, prior epidemiologic studies had less than 10 years of follow-up after blood collection (2, 3) or had small numbers of cases (4) (5) (6) (7) , precluding a detailed analysis by time between blood collection and diagnosis.
Therefore, we examined the relationship between prolactin and risk of breast cancer for prolactin levels measured <10 versus !10 years before breast cancer diagnosis (or reference date for matched controls) in a nested case-control study in the Nurses' Health Study (NHS) and NHSII, with up to 20 years of follow-up. We then evaluated this association in a subset of NHS women who provided blood samples twice, approximately 10 years apart, to allow for simultaneous control of prolactin levels at two points in time. In addition, we evaluated potential differences in association by menopausal status, associations by tumor characteristics, and a continuous analysis of the prolactin association by time between blood collection and diagnosis. Compared with our earlier analysis (2) , this study contains nearly 1,400 more cases and an additional 10 years of follow-up.
Materials and Methods

Study population
The NHS is a prospective cohort study established in 1976, when 121,700 U.S. female, registered nurses completed a baseline questionnaire (ages 30-55 years). Similarly, the NHSII was established in 1989 with 116,430 women, ages 25 to 42 years. Women in both cohorts consented to participate and have completed biennial questionnaires since study inception to report exposure status and disease diagnoses.
From 1989 to 1990, 32,826 NHS women, ages 43 to 70 years, submitted a heparin blood sample and completed a short questionnaire (9) . Participants were mailed a blood collection kit and shipped back the specimen with an ice pack by overnight courier to our laboratory, where it was processed and separated into plasma, red blood cell, and white blood cell components. Then, from 2000 to 2002, we collected a second blood sample from a subset of these women (n ¼ 18,743 women, ages 53-80 years and >98% postmenopausal) using the same protocol as in the original collection (10) .
In the NHSII, blood samples were collected from 29,611 women (ages 32-54 years) between 1996 and 1999 (11) . Briefly, premenopausal women (n ¼ 18,521) who had not taken hormones, been pregnant, or lactated within the previous 6 months provided a blood sample drawn on the third to fifth day of the menstrual cycle (follicular) and another on the seventh to ninth day before the anticipated start date of their next cycle (luteal); these are called timed samples. Plasma collected in the follicular phase was aliquoted by the participant and frozen. All other women (n ¼ 11,090) provided a single untimed blood sample. Luteal and untimed samples were shipped and processed similarly to the NHS.
All samples have been stored in liquid nitrogen freezers since collection. Prolactin has shown to be stable in whole blood that remained unprocessed for 24 to 48 hours (12) . Follow-up of the NHS blood cohort was 97% in 2010 and of the NHSII blood cohort was 95% in 2009. These studies were approved by the Committee on the Use of Human Subjects in Research at the Brigham and Women's Hospital (Boston, MA).
We considered a woman to be premenopausal if: (i) she gave timed samples, (ii) her periods had not ceased, or (iii) she had a hysterectomy with at least 1 ovary remaining and was 47 years or younger (nonsmokers) or 45 years or younger (smokers). We considered a woman to be postmenopausal if: (i) her natural menstrual periods had ceased permanently, (ii) she had a bilateral oophorectomy, or (iii) she had a hysterectomy with at least 1 ovary remaining and was 56 years or older (nonsmokers) or 54 years or older (smokers). The remaining women, most of whom had a simple hysterectomy and were 48 to 55 years old, were of unknown menopausal status.
We included cases diagnosed after blood collection but before June 1, 2010 (NHS) or June 1, 2009 (NHSII). We previously published on cases diagnosed through June 1, 2000 in the NHS and June 1, 2003 in the NHSII (2) . Cases were matched to 1 or 2 controls on menopausal status at baseline and diagnosis (premenopausal, postmenopausal, or unknown), age (AE2 years), month of blood collection (AE1 month), time of day of blood draw (in 2-hour increments), fasting status (<8 vs. !8 hours), postmenopausal hormone use at blood draw if postmenopausal (yes vs. no), and luteal day of blood draw if providing a timed sample.
Laboratory assays
Prolactin was measured by microparticle enzyme immunoassay. Samples were assayed at the Clinical Laboratory Research Core at the Massachusetts General Hospital in 11 batches, using the ARCHITECT chemiluminescence immunoassay system (Abbott Diagnostics), except for 164 cases and 245 controls (NHS) assayed by Christopher Longcope (University of Massachusetts Medical Center, Worcester, MA), in three batches, using the IMx System (Abbott Laboratory). The correlation between the two laboratories was 0.91 and across different batches within the same dataset was more than 0.95 (13) . The limit of detection was 0.6 ng/mL; no samples were below the limit of detection.
In the NHS, we assayed prolactin levels in the baseline blood samples of all cases (invasive and in situ) and matched controls diagnosed through 2006 and invasive cases and matched controls diagnosed from 2006 to 2010. In addition, for NHS cases and matched controls diagnosed from 2000 to 2010, we also assayed their second blood sample if one was available; the blood had to have been collected before disease diagnosis. In the NHSII, we assayed prolactin levels in the baseline blood samples of all cases and matched controls The intraclass correlation (ICC) over 3 years has been assessed previously among postmenopausal women (ICC ¼ 0.53; ref. 14) and among premenopausal women (15) ; in the latter population, the ICC in the follicular phase was 0.55, in the luteal phase was 0.41, and for the average of the two phases was 0.64. As there was not a substantial difference in prolactin levels by menstrual phase and the ICC was the highest for the average of the follicular and luteal levels, we used the average levels for NHSII cases and controls with timed samples. Casecontrol sets, samples from the baseline and follow-up blood collections (NHS), and follicular and luteal samples (NHSII) were assayed together, ordered randomly within a set, and labeled with unique IDs. Case-control sets were randomly ordered within a batch, although NHS and NHSII samples were assayed in separate batches. The mean coefficient of variation from blinded replicate samples across all batches was 7.8% (SD ¼ 3.5%).
Statistical analysis
Outliers (>139 ng/mL, n ¼ 10; <0.6 ng/mL, n ¼ 1) were excluded (16) . We had 2,904 distinct cases and 4,748 distinct controls available for the analysis; of these, 518 cases and 613 controls from the NHS had two prolactin measures from the baseline and follow-up blood collections. Using all the data, there were 2,468 cases and 4,021 controls with prolactin assayed on samples collected <10 years before diagnosis in cases/reference date for controls (this was set to be the same as the diagnosis date of the matched case), and 953 cases and 1,339 controls with prolactin assayed on samples collected !10 years before diagnosis/reference date. Mean prolactin concentrations in quality control samples differed slightly by batch, indicating some laboratory drift over time. Therefore, we adjusted prolactin levels for batch according to the methods described by Rosner and colleagues (17) .
Relative risks (RR) and 95% confidence intervals (CI) were determined using unconditional logistic regression comparing quartiles (cut-off points based on control distribution in the entire dataset) of prolactin concentrations for samples collected <10 and !10 years or more before diagnosis (18) . The results for unconditional logistic regression were similar to those using conditional logistic regression (data not shown); the former was used to maximize the number of controls in each analysis to increase statistical power. Tests for trend were modeled using quartile medians and assessed using the Wald statistic. When using all samples, we conducted separate models for prolactin levels measured <10 years before diagnosis and !10 years before diagnosis. We adjusted for age at blood draw, date of blood draw, fasting status and time of day of blood draw, menopausal status/postmenopausal hormone (PMH) use at blood draw, body mass index (BMI), age at menarche, history of benign breast disease (BBD), family history of breast cancer, age at menopause, average childhood body size at ages 5 and 10, and cohort. We considered separate adjustment for parity, as this may be part of the biologic pathway through which prolactin affects breast cancer (19) . We investigated potential effect modification by menopausal status at blood collection by including a multiplicative interaction term between menopausal status and the prolactin quartile median variable, using the Wald test; we used a similar approach to assess potential effect modification by PMH use among postmenopausal women and parity.
Among cases and controls who provided two blood samples, we simultaneously adjusted for prolactin values measured in samples from 1989 to 1990 and 2000 to 2002. The ICC over 10 years calculated in the NHS women who gave 2 blood samples was 0.39 (95% CI, 0.34-0.44); the ICC was similar regardless of menopausal status at the 2 blood draws (data not shown). We also evaluated the associations of average prolactin levels across the two blood collections, the percentage change in prolactin levels over time, and a cross-classification of values (cut-off point at the median). We examined all women and those women who were postmenopausal at both blood collections. These models were adjusted for age at first blood draw, date of first blood draw, time between first and second blood draw, fasting status and time of day of both blood draws, menopausal status/ PMH use at both blood draws, BMI at first blood draw, change in weight between blood draws, age at menarche, history of BBD, family history of breast cancer, age at menopause at second blood draw, and average childhood body size at ages 5 and 10. For the percentage change analysis, we additionally adjusted for ln-transformed prolactin levels in 1989 to 1990 (baseline).
Among postmenopausal women with blood samples collected within 10 years of diagnosis (the only group in which we observed significant association), we further stratified by tumor invasiveness, estrogen receptor (ER) and progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, histologic type, tumor size, grade, lymph node status, and luminal A (ER þ or PR þ , HER2 geneity were assessed using polytomous unconditional logistic regression (18) . We also evaluated associations for triple negative tumors (ER, PR, and HER2 negative) and cases who had recurrent breast cancer or died from breast cancer. To more carefully evaluate whether the effect of prolactin levels on the risk of breast cancer depended on the duration of time between blood draw and cancer diagnosis, we estimated a time-varying hazard ratio (HR) and 95% CI for breast cancer, adjusting for covariates as noted earlier. We treated time from blood draw to breast cancer diagnosis as the outcome variable, which is observed exactly among cases and right-censored at the last follow-up time (June 1, 2010) for controls. We evaluated postmenopausal women comparing prolactin levels above versus below the median.
All P values were 2-sided and were considered statistically significant if less than 0.05. All analyses were conducted using SAS, version 9.1 (SAS Institute Inc., Cary, North Carolina), STATA, version 12.1 (StataCorp. College Station, Texas), and R software, version 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Among cases and controls whose blood was drawn <10 years before diagnosis (proximate) or 10 to 20 years before diagnosis (distant), cases were more likely to have a history of BBD and a family history of breast cancer, but lower parity compared with controls (Table 1A) . Median prolactin levels were slightly higher in cases with a proximate blood draw than controls (11.7 ng/mL in cases and 11.2 ng/mL in controls), but levels were more similar comparing cases with a distant blood draw versus controls (10.7 vs. 10.5 ng/mL, respectively). Results were similar for women who provided samples at both blood collections (Table 1B) .
In multivariate analyses, we observed an increased risk for higher proximate prolactin levels [RR, >15.7 vs. 8.1 ng/mL (i.e., top vs. bottom quartile) ¼ 1.20; 95% CI, 1.03-1.40; P trend ¼ 0.005], but not for distant levels (comparable RR ¼ 0.97; P trend ¼ 0.94; Table 2 ). The positive association for proximate blood levels was only observed in postmenopausal women (comparable RR ¼ 1.37; P trend ¼ 0.0002; n ¼ 1,445 cases) and not in premenopausal women (comparable RR ¼ 1.05; P trend ¼ 0.54; n ¼ 1,023 cases), with a P heterogeneity ¼ 0.01. Distant prolactin levels measured during premenopause or postmenopause were not associated with breast cancer risk. As the majority of premenopausal women were from the NHSII and most postmenopausal women were from the NHS, we considered whether there was heterogeneity by cohort. The P heterogeneity by cohort was 0.17. Associations for proximate prolactin levels were stronger for ER þ disease; comparing women with >15.7
versus <8.1 ng/mL of prolactin, the RR was 1. PMH use among postmenopausal women (P interaction at proximate blood draw ¼ 0.65), by parity (P interaction ¼ 0.31), and after excluding women taking oral steroids or antidepressant medications at blood draw (data not shown).
We conducted further analyses among women who provided two blood samples (Table 3) . Among all women (n ¼ 518 cases and 613 controls), when modeling proximate and distant values simultaneously, we observed an RR ¼ 1.40 (95% CI, 0.96-2.06; P trend ¼ 0.03) comparing the top versus bottom quartile for proximate blood levels, but no association for distant levels (RR ¼ 0.83; P trend ¼ 0.43), (P interaction , proximate vs. distant ¼ 0.07). Among 322 cases and 420 controls who were postmenopausal at both blood draws, the RR comparing women with prolactin >15.7 versus 8.1 ng/mL was 1.75 (P trend ¼ 0.007) for proximate prolactin and 0.66 (P trend ¼ 0.11) for distant prolactin (P interaction ¼ 0.01). The average of the prolactin levels from the two blood collections was not associated with breast cancer risk. However, there was a suggestive positive association for postmenopausal women with a large positive change in prolactin levels between the two blood draws (RR, > 41.6% vs. À27% change ¼ 1.53; 95% CI, 0.88-2.66; P trend ¼ 0.05). In addition, when stratifying prolactin levels from the two blood draws, only women with prolactin levels above the median for the proximate blood had an increased risk. The results were similar, although not statistically significant, when examining ER þ cases (n ¼ 350 total ER þ cases with two blood samples and 226 postmenopausal ER þ cases; data not shown). Unconditional logistic regression models to calculate RRs and 95% CIs, adjusting for age at first blood draw (continuous), date of first blood draw (continuous), time between first and second blood draw (continuous), fasting status and time of day of both blood draws (fasting and morning draw, other), menopausal status/PMH use at both blood draws (premenopausal/unknown, postmenopausal not using PMH, postmenopausal using PMH), BMI at first blood draw (continuous), change in weight between blood draws (continuous), age at menarche (continuous), history of BBD (yes, no), family history of breast cancer (yes, no), age at menopause at second blood draw (continuous), average childhood body size at ages 5 and 10 (continuous). The analysis of postmenopausal women included 321 cases and 419 controls who were postmenopausal at both blood collections. c Model additionally adjusted for continuous ln-transformed prolactin concentrations at first blood draw.
Among postmenopausal women in which we had proximate prolactin levels measured, we evaluated associations by breast cancer phenotypes ( When evaluating the relationship of time between blood draw and diagnosis with risk of breast cancer, comparing postmenopausal women with prolactin levels above versus below the median, we observed that there was a linear decline in the association as time between blood draw and diagnosis increased for total breast cancer (Fig. 1) . The association became non-statistically significant at approximately 10 years after blood draw, consistent with our earlier results. Results were similar for ER þ disease (data not shown).
Discussion
This is the first study to examine the potential influence of the timing of prolactin exposure in relation to breast cancer diagnosis. This was possible because we had up to 20 years of follow-up, more than 2,900 cases, and, in a subset of women, 2 blood samples collected 10 years apart. In this study, we observed that prolactin was significantly positively associated with risk only when measured within 10 years of diagnosis. This association appeared to be restricted to postmenopausal women and was strongest for ER þ disease, as well as for lymph node-positive tumors. Importantly, among a subset of women who provided two blood samples about 10 years apart, we observed a similar positive association for proximate prolactin levels in an analysis that simultaneously adjusted for proximate and distant prolactin levels. Our results generally are consistent with our previous analysis in the NHS and NHSII (2), which included more than 1,500 cases with 10 years of follow-up, as well as the largest other prior study (3) . In our earlier and current analyses, we observed a positive association between prolactin and breast cancer risk that was stronger for ER þ disease and appeared to attenuate with time between blood collection and diagnosis. However, one key difference emerged between our earlier and the current study-in the current study, we did not observe an association among premenopausal women. One possible reason for this difference is that we had than double the number of premenopausal women at blood draw in the present analysis. These newly added cases were more likely to be postmenopausal at diagnosis than in the initial study, although the association was similar by menopausal status at diagnosis (RR, top vs. bottom quartile, premenopausal at blood and diagnosis ¼ 1.11 and RR, premenopausal at blood and postmenopausal at diagnosis ¼ 0.94). Our expanded analysis strongly suggests that prolactin levels measured during the postmenopausal period are more important in predicting breast cancer risk than premenopausal levels. In this study, with up to 20 years of follow-up, we were able to carefully examine the relationship of prolactin with risk of breast cancer by time between blood draw and diagnosis. In categorical and continuous analyses, we observed that prolactin was only associated with breast cancer risk when assessed within 10 years before diagnosis, but no associations were observed for blood sampled 10 to 20 years before diagnosis. This is in contrast to what was observed for estradiol and testosterone in the same population, in which levels predicted risk for up to 16 to 20 years (10). In continuous analyses, the prolactin-breast cancer relationship in postmenopausal women decreased linearly as time between blood draw and diagnosis increased. This may be, in part, because the within person ICC of prolactin in postmenopausal women over 3 years was about 0.53 (14) . Thus, as time after blood draw increases, the single blood value measured at baseline may become less reflective of a woman's more recent exposure. Interestingly, the ICC over 10 years was only modestly weaker (ICC ¼ 0.39). Another possible reason for the attenuation of the association is that breast tumors can secrete prolactin, possibly increasing circulating levels (20) (21) (22) , suggesting that prolactin may act as both a tumor and risk marker. However, this likely would only explain a stronger association within the first 2 to 4 years of follow-up, but we observed a significant association for up to 10 years after blood draw.
Nevertheless, there may be a biologic reason for this attenuation in the association over time. In vitro and in vivo studies strongly support that prolactin is involved in processes related to late-stage carcinogenic effects of breast cancer, including increasing cell proliferation and reducing apoptosis (reviewed in refs. 1, 8, 23, 24) , although these also can be important in early carcinogenesis. Furthermore, substantial evidence suggests that prolactin is involved in angiogenesis and cell migration (25) (26) (27) (28) , which may lead to increased metastases (25, 29) . Thus, it is possible that high circulating prolactin levels are important only after a preclinical lesion has developed and promotes latestage carcinogenesis. This is further supported by our results suggesting that prolactin was more strongly associated with invasive tumors and lymph-node positive disease.
As in our earlier work, prolactin was only associated with ER þ disease. Biologic data suggest that estradiol and prolactin can act synergistically on cell proliferation (30, 31) . This is supported by a separate analysis within the NHS among postmenopausal women not using PMH, in which we observed that women with high levels for multiple estrogens, androgens, and prolactin had the highest risk of breast cancer (32) . Interestingly, transgenic mouse models with constituent prolactin expression in mammary tumors led to tumors that This study has several strengths and limitations. Notably, we had identified nearly 2,900 cases over 20 years of follow-up, with excellent epidemiologic data and breast cancer phenotype information. Furthermore, in a subset of cases and controls, we were able to measure prolactin levels twice about 10 years apart to assess the influence of adjusting for proximate and distant prolactin levels simultaneously. There were fewer women with prolactin measured during premenopause; however, we had 80% power to detect an association as strong as that seen in postmenopausal women at a type I error of 0.05. As noted earlier, prolactin has some within-person variability over time, which likely attenuates our effect estimates. Using the ICC of 0.53 from our previous reproducibility study (13) , the RR for total breast cancer comparing the top with bottom quartile of prolactin for postmenopausal women would increase from 1.37 to 1.81, accounting for measurement error (18) . Furthermore, the immunoassay for prolactin measures all isoforms, which have differing biologic activities (36, 37) . Using an assay that considers the biologic activity of prolactin in plasma may provide further insight into the prolactin-breast cancer relationship.
In summary, our study provides further evidence that prolactin is involved in the etiology of breast cancer, particularly among postmenopausal women and for ER þ disease. Risk appears to be increased in postmenopausal women with prolactin concentrations above 11.0 ng/mL, which is well within the normal range (38) . Importantly, the association is only observed for prolactin levels measured within 10 years of diagnosis. This is consistent with biologic data that prolactin is important in processes generally thought to be involved in tumor promotion, suggesting that prolactin primarily plays a role in tumor development when a preclinical lesion has been established. Although the risk estimates are lower than those for estradiol or testosterone, prolactin should be considered for inclusion in risk prediction models for postmenopausal women, particularly because it is not strongly correlated with these other hormones. However, prolactin levels would need to be assessed at least every 10 years.
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